Overall rank by patents
#44,813
Across all tracked assignees
USPTO PatentsView assignee record - 5 granted patents across 3 technology areas, active 2023–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).
The verdict
Alida holds 5 US patents across 3 technology areas, rank #44,813 of 50,000 tracked assignees.
Alida Biosciences Inc. has been granted 5 US utility patents between 2023 and 2025, placing Alida Biosciences Inc. at rank #44,813 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 25.6 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a US Corporation, Alida Biosciences Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Alida sits between Alfa Biogene International B.v. (5 patents, rank #44,809) and Alio, Inc. (5 patents, rank #44,817) - the closest US assignees by grant volume. The composite Innovation Score of 40.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2023 through 2025, with 5 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Alida Biosciences Inc.'s 25.6 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Alida Biosciences Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Alfa Biogene International B.V.
5 patents
Alfelder Kunststoffwerke Herm. Meyer GmbH
5 patents
Alger Alternative Energy, LLC
5 patents
Alibaba Cloud Computing Co., Ltd.
5 patents
AlignMed, Inc.
5 patents
Aligned As Designed, LLC
5 patents
Alimentary Health Ltd.
5 patents
Alio, Inc.
5 patents
Alida Biosciences Inc.
5 patents
What this shows Alida holds 5 patents at rank #44,813, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #44,813 in granted patent volume.
Other assignees with the most granted patents in Alida's primary technology class.
Alida's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
41 Top 35% higher than 65% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2023 | 1 | 20.0% |
| 2024 | 1 | 20.0% |
| 2025 | 3 | 60.0% |
Top 3 of 3 technology areas
Overall rank by patents
#44,813
Across all tracked assignees
40.6 out of 100
How to use this portfolio
Alida's 5 grants land it in the top 35% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.